New blood test could detect ovarian cancer before it develops

Researchers say an experimental blood test may detect microscopic precancerous changes linked to ovarian cancer before tumours form. The approach could eventually help doctors assess risk and guide decisions about preventive surgery, particularly for women at high risk.

The study examined Tu-stroma, an RNA biomarker in blood, for signs of serous tubal intraepithelial carcinoma, a precursor to the most common and deadly type of ovarian cancer. It detected these lesions in 92.3% of affected women and correctly identified 98.2% of women without them; modelling in a high-risk group estimated 72% detection and near-100% accuracy for negative cases. The test is still experimental and needs further study over time before it can be clinically validated.